🇺🇸 FDA
Pipeline program

TAGRISSO 80 mg film-coated tablets, TAGRISSO 40 mg film-coated tablets, Placebo

D516FC00001(ADAURA2)

Phase 3 small_molecule active

Quick answer

TAGRISSO 80 mg film-coated tablets, TAGRISSO 40 mg film-coated tablets, Placebo for Stage IA2-IA3 non-small cell lung carcinoma, with EGFR mutation type (Ex19del, L858R), following complete tumour resection. is a Phase 3 program (small_molecule) at AstraZeneca AB with 1 ClinicalTrials.gov record(s).

Program details

Company
AstraZeneca AB
Indication
Stage IA2-IA3 non-small cell lung carcinoma, with EGFR mutation type (Ex19del, L858R), following complete tumour resection.
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials